04:46 PM EDT, 03/10/2025 (MT Newswires) -- Coherus BioSciences ( CHRS ) reported a Q4 non-GAAP net loss late Monday of $0.28 per diluted share, narrowing from a loss of $0.62 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.19.

Total revenue for the quarter ended Dec. 31 was $54.1 million down from $91.5 million a year earlier.

Analysts polled by FactSet expected $44.1 million.

Chief Executive Officer Denny Lanfear said the company expects

cash position of about $250 million upon the completion of the UDENYCA divestiture and pay-off of its "significant" debt and royalty obligations.

"These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026," Lanfear said.